Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Malignancy, Hematologic: early-phase trial registry

1 of 1 indexed Malignancy, Hematologic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Malignancy, Hematologic: 1 US clinical trial tracked, 1 recruiting.

Malignancy, Hematologic is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 1 of these trials.

Enrollment posture brief

Registry condition malignancy-hematologic

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Malignancy, Hematologic (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Malignancy, Hematologic

Malignancy, Hematologic lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignancy, Hematologic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignancy, Hematologic is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Malignancy, Hematologic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

TruSight Oncology (TSO) 500 Device
1 trials
fludarabine phosphate Drug
1 trials
aldesleukin Drug
1 trials
cyclophosphamide Drug
1 trials
Individual Patient TCR-Transduced PBL Biological
1 trials

US sites by state

Facility locations filed on Malignancy, Hematologic trials. A trial with sites in several states counts in each.

Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignancy, Hematologic page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignancy, Hematologic condition card totals 1 registered trials; most-linked intervention TruSight Oncology (TSO) 500; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.